Mainz Biomed B.V. (MYNZ) Stock

About Mainz Biomed B.V.

Mainz Biomed B.V. is a German company specializing in molecular genetics for the development of cancer diagnostics. The firm engineers both in-vitro diagnostic (IVD) tools and assays designed exclusively for research, primarily catering to clinical applications within human genetics. Among its key offerings is ColoAlert, a screening test for detecting colorectal cancer. Additionally, they are developing PancAlert, a promising product candidate intended for pancreatic cancer screening. Beyond cancer, Mainz Biomed also provides GenoStrip, a molecular genetic solution for identifying pathogens in various environments. Established in 2008, the company maintains its headquarters in Mainz, Germany.

Mainz Biomed B.V. is headquartered in DE.

Mainz Biomed B.V. (MYNZ) stock trades at $3.59 with a market capitalization of $14.69M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.93, reflecting a net loss over the last twelve months, price-to-book of 3.24, price-to-sales of 55.00. Over the past 52 weeks the stock has ranged between $0.55 and $5.34, and currently trades 32.8% below its 52-week high.

On profitability, Mainz Biomed B.V. generates a return on equity (ROE) of -325.93% (negative, reflecting a net loss), return on capital employed of -170.15%, an operating margin of -1300.00%, a net profit margin of -1600.00%.

Official website: mainzbiomed.com